Pagari Life Science

Pagari Life Science is an early-stage biotech developing a proprietary platform for anti-herpetic and wound healing drugs. The company has already commercialized its first product, Helocaine, for over-the-counter treatment of cold sores and minor skin injuries. Its pipeline includes preclinical programs for genital herpes and shingles, developed in partnership with the NIH/NIAID, targeting significant unmet needs in pain management and viral resolution. Pagari operates as a private, likely pre-revenue entity leveraging external research collaborations to advance its core technology.

Proprietary small-molecule platform for topical application featuring dual mechanism of antiviral activity and local analgesia/pain elimination.

Faces competition in OTC cold sore market from brands like Abreva and numerous generics. In prescription antivirals, competes with established systemic drugs (e.g., valacyclovir) and large pharma. The wound care space is fragmented with many established players. Pagari's differentiation hinges on its combined antiviral and analgesic effect.